Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Adierazpen geografikoek jatorrizko produktu baten izena eremu geografiko batetik babesten dute, eta adierazpen horri esker kalitate, ospe edo beste ezaugarri jakin batzuk ditu. Ezagutu zer diren, zein den erregistratzeko prozedura eta zer onura dituzten.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
312
resultados
Última actualización
13/09/2026 [07:20:00]
Resultados 50 a 75 de 312
Resumen de: WO2026177204A1
The purpose of the present invention is to provide a novel naturally derived cellular vesicle staining agent that can easily fluorescently stain cellular vesicles and that is safe even when introduced into the body, and to provide a cellular vesicle staining agent having anti-inflammatory activity. The purpose of the present invention is also to provide a method for producing a cellular vesicle staining agent, whereby the cellular vesicle staining agent can be easily produced. Another purpose of the present invention is to provide a method for detecting cellular vesicles using the cellular vesicle staining agent. The present invention provides: a cellular vesicle staining agent comprising chlorophyll or a chlorophyll derivative; an anti-inflammatory agent comprising chlorophyll or a chlorophyll derivative as an active ingredient; a method for producing a cellular vesicle staining agent, the method comprising a step for extracting a cellular vesicle staining agent from a photosynthetic organism; and a method for detecting a cellular vesicle in a sample or in a body using the cellular vesicle staining agent.
Resumen de: US20260248877A1
0000 The present invention provides inhibitory peptides for use in the diagnostic and/or treatment of tauopathies, in particular Alzheimer's Disease and Pick's Disease. The inhibitory peptides comprise a hexapeptide sequence that specifically inhibits interactions of the PHF6 sequence within pathological Tau protein.
Resumen de: US20260251634A1
A method of analyzing neurons includes: identifying a cell region by identifying a region of a neurite or a region of a cell body of a neuron on the basis of time-series images obtained by imaging the neuron in time series; detecting aggregates by imaging, in time series, first fluorescent protein tagged to specific protein expressed in the neuron and detecting presence or absence of aggregates of the specific protein aggregated in the region of the neurite or the region of the cell body identified in the identifying the cell region on the basis of luminance of the first fluorescent protein included in the time-series images; and performing an analysis by classifying the neuron into a plurality of groups on the basis of a detection result of the detecting the aggregates and analyzing a survival state of the neuron for each of the groups.
Resumen de: EP4796928A1
The present disclosure relates to an in vitro method for diagnosing Alzheimer's disease (AD) in a subject, the method comprising a step of determining the level of β-secretase 1 protein (BACE-1) comprised in a population of brain-derived extracellular vesicles (BDEVs) in an isolated sample obtained from the subject, particularly wherein the population of BDEVs carry neuroligin-3 (NLGN3), wherein when the level of BACE-1 is equal to or higher than a reference this is indicative of a positive diagnosis of Alzheimer's disease. Also provided herein are methods of determining the classification of a subject according to the A/T/N system, methods for recommending a medical regimen, methods for determining therapeutic efficacy of a medical regiment, as well as methods of treatment for AD and AD-associated pathologies in a subject. Finally, the present disclosure provides kits and devices comprising: a) means for capturing a population of brain-derived extracellular vesicles; b) means for detecting the presence and/or for determining the level of BACE-1 protein; and optionally, c) a solid support.
Resumen de: WO2025085755A1
Disclosed are methods of detecting or quantifying a pathology -related or pathology-protective-pathway in a subject comprising combining a first ligand with a sample obtained from the subject comprising an extracellular particle, wherein the first ligand binds to a cell-type specific marker on the extracellular particle; combining a second ligand with the sample, wherein the second ligand binds to a pathology-related or pathology-protective pathway molecule on the extracellular particle; combining a donor bead to the sample, wherein the donor bead binds to the first ligand or second ligand; combining an acceptor bead to the sample, wherein the acceptor bead binds to the first ligand or second ligand, wherein the donor bead and acceptor bead do not bind to the same ligand; triggering the donor bead to activate the acceptor bead to produce a signal; wherein the amount, presence, or absence of a signal indicates the amount, presence, or absence of a pathological condition in the subject.
Resumen de: WO2025081242A1
The present disclosure relates to compositions comprising a solid surface and two or more capture agents that bind to extracellular vesicles (EVs) for capturing EVs derived from cells of the nervous system. The present disclosure further relates to methods or uses of such compositions for treating, diagnosing and/or assessing the likelihood of a subject suffering from a neurodegenerative disease.
Resumen de: EP4796929A2
0001 A method is provided for determining the presence of soluble, misfolded α-synuclein protein in a biological sample. The method comprises contacting the biological sample with a pre-incubation mixture, the pre-incubation mixture comprising: a monomeric α-synuclein protein; a buffer composition; a salt; and an indicator, to form an incubation mixture. An incubation cycle is conducted on the incubation mixture in the presence of either a silicon nitride bead or a borosilicate glass bead having a diameter of from about 1 mm to about 5 mm. The method further comprises determining if a detectable amount of misfolded α-synuclein aggregate is present in the biological sample.
Resumen de: EP4796930A2
Disclosed herein are methods of detecting a plurality of targets comprising different nucleic acid sequences or different proteins within an optically resolved volume of a cell in situ.
Resumen de: CN122629217A
0001 本发明公开了一种用于HIV相关无症状神经认知障碍（ANI）诊断的代谢组学‑肠道微生物标志物组合，包括代谢组学标志物和肠道微生物标志物，其中代谢组学标志物包括血浆标志物和粪便标志物，血浆标志物包括Asp‑Asn和花生四烯酸，粪便标志物包括组氨酸、赖氨酸、鸟氨酸以及吲哚乳酸；肠道微生物标志物包括门水平标志物和属水平标志物，门水平标志物包括厚壁菌门、放线菌门以及变形菌门微生物，属水平标志物包括普拉梭菌属、小杆菌属、克雷伯氏菌属以及普雷沃氏菌属。该标志物组合整合了代谢组学与肠道微生物的核心差异特征，诊断特异性和敏感性高，能够有效区分ANI患者与CI患者及健康人群，为HAND靶向干预提供了明确靶点，具有重要的临床应用价值。
Resumen de: CN122631731A
0001 本发明公开了表位分子印迹膜库的构建结合场效应晶体管用于检测超灵敏生物检测的方法，用于多种生物分子的检测；同时将制备的表位分子印迹膜库与场效应晶体管技术相结合开发一种高灵敏生物检测的方法，属于生物传感器技术领域；通过在铜箔表面制备分子印迹膜，并且印迹不同的肽段分子从而建立分子印迹膜库；在铜箔刻蚀去除后将膜转移到石墨烯表面构建场效应晶体管，借助石墨烯的高灵敏可以实现不同分子的检测；肽段或蛋白可以进入到分子印迹的特异性空腔中，进而引起电信号的变化，实现生物分子的放大检测；该发明首次实现表位分子印迹膜库的建立，证明了方法的通用性，实现了多种生物样品的高特异性，快速、超敏的检测。
Resumen de: WO2025032091A1
The present invention relates to a splice variant of a CERT1 protein that acts as a biomarker for a TDP-43 pathology, in particular motor neuron diseases such as amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD), but also other neurological diseases, such as Alzheimer's disease. In particular, the present invention relates to methods for identifying a splice variant of CERT1 comprising a cryptic peptide sequence, and to related methods of identifying a TDP-43 pathology and/or reduced TDP-43 function in a subject and to methods for predicting whether a therapy is likely to be successful. Also claimed are antibodies binding to the CERT1 splice variant and kits comprising the antibody.
Resumen de: WO2025035206A1
The invention describes a transgenic, non-human animal model, for testing post-natal, conditionally inducible plasmalogen deficiency. The animal model's genome is equipped with a gene that is capable of regulating the plasmalogen biosynthetic pathway, where the gene has a regulatory region. Within the regulatory region there is at least one conditionally inducible gene editing site that blocks the expression of the gene when edited. The genome also has a nucleic acid editing sequence integrated at a separate locus from the gene which encodes a gene product. The gene product edits the gene editing site when conditionally induced that eventually down-regulates or disrupts the plasmalogen biosynthetic pathway. Methods and uses involving the transgenic, non-human animal model are also provided.
Resumen de: CN122628189A
0001 本申请公开了一种用于磷酸化Tau蛋白pTau217检测的抗体、免疫检测方法及应用。本申请抗体包括T217‑3D6抗体；T217‑3D6的轻链CDR1、CDR2和CDR3依序为SEQ ID NO.1至3所示序列，重链CDR1、CDR2和CDR3依序为SEQ ID NO.4至6所示序列。基于本申请抗体对磷酸化Tau蛋白pTau217进行免疫检测，操作简单、灵敏度高、特异性强，可实现磷酸化Tau蛋白pTau217快速检测，对评估Tau蛋白磷酸化水平和Tau蛋白pTau217磷酸化相关检测具有重要意义。
Resumen de: KR20160146760A
0001 An anti-aging agent derived from a natural product is provided. At least one selected from the group consisting of imidazolidine peptides and metabolites thereof. The present invention also provides an agent for improving neuropsychological function comprising at least one selected from the group consisting of imidazocidepeptides and metabolites thereof as an active ingredient. The present invention is also directed to an agent for modulating the expression of a transporter, such as SLC23A2, containing at least one selected from the group consisting of imidadocidepeptides and metabolites thereof, an imidazocidepeptide and a metabolite thereof An agent for controlling the concentration of cytokine such as IP-10 containing at least one in blood, an expression analysis method for detecting improvement or deformation of neuropsychological function, a kit for detecting improvement or deformation of neuropsychological function .
Resumen de: CN122612933A
0001 本发明公开了一种血清α‑突触核蛋白种子体外扩增检测方法、试剂盒及其应用，属于生物医学领域。本发明提供的血清α‑突触核蛋白种子体外扩增检测方法包括以下步骤：将待测血清裂解，离心后收集第一上清液；所述第一上清液经有机溶剂萃取脂质，收集水相；所述水相加入蛋白酶K消化，再次离心后收集第二上清液；所述第二上清液经超滤后收集截留液，得到预处理后的种子富集血清样本；将所述预处理后的种子富集血清样本加入反应液中进行SAA扩增反应。本发明基于新的血清预处理思路和优化的SAA扩增反应条件，提出了一种新的血清α‑突触核蛋白种子体外扩增检测方法及配套试剂盒，以满足标准化、高通量、跨中心一致性的临床检测需求。
Resumen de: CN122612931A
0001 本发明涉及绝经后女性认知障碍诊断技术领域，公开了一种用于诊断或辅助诊断绝经后女性认知障碍的试剂盒及应用。该试剂盒包括用于检测血浆中GFAP、p‑tau181、Orexin‑A等生物标志物表达水平的检测试剂。本发明首次发现并验证了GFAP、p‑tau181等生物标志物在更年期女性认知障碍患者中显著高表达，可作为诊断或辅助诊断的标志物，为绝经后女性认知障碍的早期诊断提供了一种新的、非侵入性的检测手段。
Resumen de: CN122609706A
本发明属于及医学诊断领域，具体而言，涉及阿尔茨海默病的诊断标志物及其应用。具体地，本发明提供了用于诊断阿尔茨海默病的靶标及其检测方法。更具体地，本发明涉及用于检测样品中UBE2D1基因表达水平的试剂在制备用于诊断阿尔茨海默病或预测阿尔茨海默病风险的组合物或试剂盒中的用途，其中，所述用于检测样品中UBE2D1基因表达水平的试剂包括：用于检测样品中UBE2D1基因的mRNA水平的试剂，用于检测样品中泛素结合酶E2D1水平或泛素结合酶E2D1相关调控蛋白水平的试剂，用于检测UBE2D1基因CpG岛甲基化水平的试剂，或其任意组合。
Resumen de: US20260243777A1
0000 The present disclosure provides a range of compositions and methods for enriching subsets of complex biological samples. Aspects of the present disclosure provide peptide-functionalized particles comprising affinities for subsets of biomolecules from complex biological samples. The present disclosure further provides methods for utilizing functionalized particles to fractionate and analyze complex biological samples.
Resumen de: WO2026174031A1
A method for identifying RNA patterns in diagnosis and treatment of thoracic aortic aneurysm disease includes performing RNA sequencing on samples; analyzing the RNA sequencing data with the performance of differential gene expression analysis focusing on differentially regulated pathways to reveal complex regulatory mechanisms; developing a machine learning model to integrate pathway-level interactions; and combining pathway- specific analysis of the RNA patterns with the machine learning model to generate predictions identifying patients likely to be susceptible to thoracic aortic aneurysm disease.
Resumen de: WO2026170288A1
Various embodiments of a wearable device for disease detection are described herein. The wearable devices include a plurality of layers including an adhesive layer for affixing the wearable device to a subject's skin and a plurality of patterned layers, each patterned layer having a sensing pattern defined thereon. When the patterned layers are assembled, the sensing patterns cooperate to define: inlet chambers adapted to receive sweat droplets, each inlet chamber having antibodies conjugated to a detection medium adapted to bind to a corresponding biomarker of interest in the sweat droplets, sensing chambers, each sensing chamber receiving the sweat droplets from at least one inlet chamber via a microchannel through capillary action and adapted to sense a corresponding biomarker of interest by binding at least a portion of the conjugate molecules associated with the corresponding biomarker, and a control chamber in fluid communication with the sensing chambers via outlet channels.
Resumen de: US20260243762A1
0000 A multimodal lateral flow assay (LFA) system for non-invasive biomarker monitoring is provided. The system includes a multimodal LFA strip having a sample-loading region for receiving a biological sample, a conjugate region containing triple-mode probes, and a membrane zone with immobilized capture and secondary antibodies that form respective test and control lines upon binding the probes. The triple-mode probes generate colorimetric, fluorescence, and surface-enhanced Raman scattering (SERS) signals. A laser-emitting module illuminates the membrane zone to excite fluorescence and SERS responses, which are detected by one or more optical detection devices. A processor performs multimodal signal mapping by analyzing fluorescence and SERS outputs to determine the quantitative concentration of the biomarker in the sample. The system enables sensitive, quantitative, and non-invasive detection of biomarkers across multiple optical modalities.
Resumen de: WO2026171791A1
The disclosure relates to a system for multiplex detection of analytes by primary translatable complexes. This refers to complexes of an antigen-specific primary antibody and oligonucleotides are used to detect multiple antigens of interest in a simultaneous manner. The linkage between primary antibody and oligonucleotides is achieved by using avidin-biotin system. Each of the multiple complexes are formed in individual reaction tubes and added simultaneously to biological specimens. The presence of antigens can be identified via various options using complementary oligonucleotides. This allows a simultaneous detection of analytes.
Resumen de: WO2026172292A1
The disclosed multiple-sample lateral flow system, device and method leverages multiple biological samples, lateral flow test and communication module (such as Bluetooth) for accurately detecting biomarkers related to one or more medical conditions. The multiple-sample lateral flow system comprises an integrated multiple test strip (IMTS) and device. The IMTS, configured to receive and process at least two biological samples, comprises first and second test zones configured to detect first and second sets of biomarkers specific to first and second biological samples that are indicative of at least one first medical condition, second medical condition. The device comprises a strip receiving unit to receive the integrated multiple test strip; an imaging sensor configured to capture images of the integrated multiple test strip; and a communication module configured to transmit the captured images to a processing unit for analysis and identification of the one or more medical conditions.
Resumen de: WO2026174301A1
The present disclosure relates to compositions and methods for regulating lipokines in age-related disorders and methods of use thereof.
Nº publicación: US20260240871A1 20/08/2026
Solicitante:
SEOUL NATIONAL UNIV R&DB FOUNDATION [KR]
SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
Resumen de: US20260240871A1
A composition includes a lysosomal ABCA1 inhibitor. The composition inhibits the transport of cellular ABCA1 to lysosomes or suppresses ABCA1 within lysosomes, by including the lysosomal ABCA1 inhibitor, thereby inhibiting lysosomal cholesterol accumulation and the production of senescence-associated secretory phenotype (SASP) factors. Therefore, the composition can be used for inhibit age-related inflammation, and prevent, improve or treat age-related musculoskeletal disorders.
BOPI
Sede Electrónica
